Abstract: A method of making a golf club head includes the steps of providing a face of a club head, the face having a ball striking surface and a perimeter defining a border of the ball striking surface, providing a golf club head body that includes a crown, a sole, a toe, and a heel, attaching the face to a front portion of the club head body, and milling the ball striking surface and an edge portion of the face to cut a machined surface into the ball striking surface and the edge portion. The milled surface includes a plurality of first grooves located along the ball striking surface and defining a first depth, and a plurality of second grooves located adjacent the perimeter along the edge portion and defining a second depth. The first depth is different than the second depth.

Abstract: A system and method for solid state metal plate repair is provided. A solid state metal plate repair system may comprise a drill, a cutter and a plug. The plug may be configured to fill a void created by the cutter. The plug may also be configured to create a metallurgical bond with the metal plate during a repair operation. The plug may also be configured to shear from the drill (e.g., drive motor) when an expected rise in torque indicates a sufficient bond has been achieved in the repair. The systems and methods described herein may be used on specialty alloys wherein other repair methods are undesirable.

Abstract: A system and method for solid state metal plate repair is provided. A solid state metal plate repair system may comprise a drill, a cutter and a plug. The plug may be configured to fill a void created by the cutter. The plug may also be configured to create a metallurgical bond with the metal plate during a repair operation. The plug may also be configured to shear from the drill (e.g., drive motor) when an expected rise in torque indicates a sufficient bond has been achieved in the repair. The systems and methods described herein may be used on specialty alloys wherein other repair methods are undesirable.

Abstract: A method of manufacturing homogenous metal matrix composite (MMC) powders and using the powders as the feedstock with cold spray deposition is described to produce composite coatings and freestanding bulk forms. Measured quantities of metal and ceramic powders having predetermined particle sizes are blended to produce homogeneous MMC powders. Spray parameters and procedures are controlled to produce dense, strong and well-bonded MMC coatings on any substrate.

Abstract: A method of manufacturing homogenous metal matrix composite (MMC) powders and using the powders as the feedstock with cold spray deposition is described to produce composite coatings and freestanding bulk forms. Measure quantities of metal and ceramic powders having predetermined particle sizes are blended to produce homogeneous MMC powders. Spray parameters and procedures are controlled to produce dense, strong and well-bonded MMC coatings on any substrate.

Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1. or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.

Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

Abstract: A microstructure-based chemical sensor that can be interrogated by a remote observer. The device acts as an electromagnetic wave filter in the optical region of the spectrum, filtering one or more wavelength bands where the band spectral notch location shifts in response to the accumulation of material on the surface of the microstructure sensor. The apparatus has a substrate having a surface relief structure containing dielectric bodies with one or more physical dimensions smaller than the wavelength of the filtered electromagnetic waves, such structures repeated in an array covering at least a portion of the surface of the substrate. A retro-reflecting structure allows interrogation of the sensor over a wide field of view. The device is particularly useful as a water monitoring device in hard to reach locations, and as a chemical warfare or explosives detector that can be read from a safe distance.

Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.

Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.

Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.

Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.

Abstract: A microstructure-based polarizer is described. The device acts as an electromagnetic wave filter in the optical region of the spectrum, filtering multiple wavelength bands and polarization states. The apparatus comprises a substrate having a surface relief structure containing dielectric bodies with physical dimensions smaller than the wavelength of the filtered electromagnetic waves, such structures repeated in an array covering at least a portion of the surface of the substrate. The disclosed structure is particularly useful as a reflective polarizer in a liquid crystal display, or as polarizing color filter elements at each pixel in a display. Other applications such as polarization encoded security labels, polarized room lighting, and color filter arrays for electronic imaging systems are made practical by the device.

Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prod rug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

Abstract: A method for depositing a metallic material onto a substrate comprises the steps of placing the substrate in a vacuum chamber, inserting a spray gun nozzle into a port of the vacuum chamber, and depositing a powdered metallic material onto a surface of the substrate without melting the powdered metal material. The depositing step comprises accelerating particles of the powdered metal materials within the vacuum chamber to a velocity so that upon impact the particles plastically deform and bond to a surface of the substrate.